Erisyon, founded in March 2018, is a pioneering company in the field of single molecule protein sequencing. Emerging from over a decade of research at the University of Texas at Austin's Center for Systems and Synthetic Biology, Erisyon aims to revolutionize disease detection, treatment, and tracking. Their core product, the world's first single-molecule protein sequencer, leverages fluorosequencing technology to offer unprecedented fidelity, sensitivity, and resolution in proteomics. Erisyon's mission is to make the world healthier, safer, and more abundant through advanced scientific discoveries.

Notable figures associated with Erisyon include its founding team of technologists and entrepreneurs who have driven the company's innovative trajectory. The company has garnered attention from investors interested in cutting-edge biotechnology. Key achievements include the successful development and commercialization of their groundbreaking protein sequencer, which has the potential to accelerate medical breakthroughs significantly. Erisyon's impact lies in its promise to transform healthcare by enabling earlier and more accurate disease detection and treatment.